New Study Shows Abatacept Delays Onset of Rheumatoid Arthritis in High-Risk Individuals
A recent study conducted by researchers at King's College London has revealed that early intervention with the drug abatacept can significantly delay the onset of rheumatoid arthritis (RA) in individuals at high risk. The study, published in The Lancet Rheumatology, followed participants for up to eight years, making it one of the longest studies of its kind. The research found that a 12-month treatment with abatacept delayed the onset of RA by up to four years compared to a placebo. This autoimmune disease, which affects about half a million people in the UK, leads to joint pain, swelling, and long-term disability. The study highlights the potential of early treatment to alter the disease's trajectory, providing patients with more symptom-free years. 
